Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors
- Author
- Erin Harris
- Published
- Thu 03 Feb 2022
- Episode Link
- None
We love to hear from our listeners. Send us a message.
Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that cause immune-related toxicities that impose significant treatment challenges with current therapies.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
